Skip to main content

Table 2 Patients characteristics according to neutrophil-to-lymphocyte ratio /platelet-to-lymphocyte ratio

From: Combination versus single-agent as palliative chemotherapy for gastric cancer

CharacteristicsTotal N (%)NLRP valuePLRP value
LowHighaLowHighb
Gender   0.116  0.562
 Male478 (69.6)229 (66.8)249 (72.4) 243 (70.6)235 (68.5) 
 Female209 (30.4)114 (33.2)95 (27.6) 101 (29.4)108 (31.5) 
Age (years)   0.375  0.235
  < 70562 (81.8)276 (80.5)286 (83.1) 275 (79.9)287 (83.7) 
  ≥ 70125 (18.2)67 (19.5)58 (16.9) 69 (20.1)56 (16.3) 
PS (ECOG)   0.020  0.333
 0, 1611 (88.9)315 (91.8)296 (86.0) 310 (90.1)301 (87.8) 
 2, 376 (11.1) c28 (8.2)48 (14.0) 34 (9.9)42 (12.2) 
Disease status   < 0.0001  < 0.0001
 Primary metastatic383 (55.7)155 (45.2)228 (66.3) 166 (48.3)217 (63.3) 
 Recurrent304 (44.3)188 (54.8)116 (33.7) 178 (51.7)126 (36.7) 
Tumor differentiation   0.166  0.777
 Well, moderate167 (24.3)92 (26.8)75 (21.8) 88 (25.6)79 (23.0) 
 Poor186 (27.1)83 (24.2)103 (29.9) 95 (27.6)91 (26.5) 
 Signet ring cell171 (24.9)81 (23.6)90 (26.2) 81 (23.5)90 (26.2) 
 Combined, others163 (23.7)87 (25.4)76 (22.1) 80 (23.3)83 (24.2) 
Peritoneal metastasis   0.039  < 0.0001
 No373 (54.3)200 (58.3)173 (50.3) 220 (64.0)153 (44.6) 
 Yes314 (45.7)143 (41.7)171(49.7) 124 (36.0)190 (55.4) 
Liver metastasis   1.000  0.004
 No535 (77.9)267 (77.8)268 (77.9) 252 (73.3)283 (82.5) 
 Yes152 (22.1)76 (22.2)76 (22.1) 92 (26.7)60 (17.5) 
1st line CTx   0.286  0.929
 Single-agent166 (24.2)89 (25.9)77 (22.4) 84 (24.4)82 (23.9) 
 Combination521 (75.8)254 (74.1)267 (77.6) 260 (75.6)261 (76.1) 
Palliative surgical resection   < 0.0001  0.775
 No549 (79.9)250 (72.9)299 (86.9) 273 (79.4)276 (80.5) 
 Yes138 (20.1)93 (27.1)45 (13.1) 71 (20.6)67 (19.5) 
PLR   < 0.0001  
 Low344 (50.1)248 (72.3)96 (27.9)  
 High343 (49.9)95 (27.7)248 (72.1)  
  1. a > median (2.67), b > median (167.21). c PS 3: 2 patients
  2. NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, N number, PS performance status, ECOG Eastern Cooperative Oncology Group, CTx Chemotherapy